[
  {
    "ts": "2026-01-12T04:24:08+00:00",
    "headline": "The Bull Case For Gilead Sciences (GILD) Could Change Following New OncoNano Drug-Delivery Collaboration",
    "summary": "On January 6, 2026, OncoNano Medicine announced a research collaboration with Gilead Sciences to test its ON-BOARD encapsulation technology with a Gilead drug candidate, with OncoNano eligible for upfront, milestone and royalty payments and up to US$300.00 million if Gilead adds a second target. This collaboration underscores Gilead’s continued push to enhance drug delivery and efficacy in its pipeline, potentially reinforcing its focus on innovative therapies. Now we’ll examine how this...",
    "url": "https://finance.yahoo.com/news/bull-case-gilead-sciences-gild-042408901.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "cce8f870-5808-38b7-a1e0-23eb861988a5",
      "content": {
        "id": "cce8f870-5808-38b7-a1e0-23eb861988a5",
        "contentType": "STORY",
        "title": "The Bull Case For Gilead Sciences (GILD) Could Change Following New OncoNano Drug-Delivery Collaboration",
        "description": "",
        "summary": "On January 6, 2026, OncoNano Medicine announced a research collaboration with Gilead Sciences to test its ON-BOARD encapsulation technology with a Gilead drug candidate, with OncoNano eligible for upfront, milestone and royalty payments and up to US$300.00 million if Gilead adds a second target. This collaboration underscores Gilead’s continued push to enhance drug delivery and efficacy in its pipeline, potentially reinforcing its focus on innovative therapies. Now we’ll examine how this...",
        "pubDate": "2026-01-12T04:24:08Z",
        "displayTime": "2026-01-12T04:24:08Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HAEiJmFsYXJTRBPxnneP6w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hXB9F2qU7k4qk3_k1DQd9A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-gilead-sciences-gild-042408901.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-gilead-sciences-gild-042408901.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-12T09:31:12+00:00",
    "headline": "UBS and Citi Go Bullish on Gilead Sciences (GILD)",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the most undervalued blue chip stocks to buy now. On January 7, 2026, reports highlighted that analysts are increasingly confident in Gilead Sciences, Inc. (NASDAQ:GILD)’s short- and medium-term outlook, driven by optimism around the company’s HIV franchise. On that day, UBS analyst Michael Yee upgraded the stock from […]",
    "url": "https://finance.yahoo.com/news/ubs-citi-bullish-gilead-sciences-093112312.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "adad85c8-339d-3e0e-b0b9-f8168603d018",
      "content": {
        "id": "adad85c8-339d-3e0e-b0b9-f8168603d018",
        "contentType": "STORY",
        "title": "UBS and Citi Go Bullish on Gilead Sciences (GILD)",
        "description": "",
        "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the most undervalued blue chip stocks to buy now. On January 7, 2026, reports highlighted that analysts are increasingly confident in Gilead Sciences, Inc. (NASDAQ:GILD)’s short- and medium-term outlook, driven by optimism around the company’s HIV franchise. On that day, UBS analyst Michael Yee upgraded the stock from […]",
        "pubDate": "2026-01-12T09:31:12Z",
        "displayTime": "2026-01-12T09:31:12Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/ae3aff8170c32ab72e21b7d307dd751f",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "UBS and Citi Go Bullish on Gilead Sciences (GILD)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QJoE63tFdMpnnrAbqprcaw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/ae3aff8170c32ab72e21b7d307dd751f.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Gi43WiQpLk0J.NMrpOdajw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/ae3aff8170c32ab72e21b7d307dd751f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ubs-citi-bullish-gilead-sciences-093112312.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ubs-citi-bullish-gilead-sciences-093112312.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]